Screener
Bausch + Lomb BLCO Pharmaceuticals — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001860742-26-000088
| (in millions) | Vision Care / Three Months Ended June 30, 2026 | Vision Care / Three Months Ended June 30, 2025 | Pharmaceuticals / Three Months Ended June 30, 2026 | Pharmaceuticals / Three Months Ended June 30, 2025 | Surgical / Three Months Ended June 30, 2026 | Surgical / Three Months Ended June 30, 2025 | Total / Three Months Ended June 30, 2026 | Total / Three Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of other revenues | — | — | — | 2 | — | — | ||
| Selling, general and administrative | 247 | 243 | 149 | 154 | 80 | 73 | ||
| Research and development | 17 | 11 | 27 | 12 | 12 | 12 | ||
| Segment Profit | $229 | $209 | $89 | $37 | $17 | $2 | 335 | 248 |
| Corporate | (170) | (170) | ||||||
| Amortization of intangible assets | (57) | (67) | ||||||
| Other expense, net | (25) | (22) | ||||||
| Operating income (loss) | 83 | (11) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's pharmaceuticals — operating income (loss)?
- Bausch + Lomb (BLCO) reported pharmaceuticals — operating income (loss) of $89M in Q2 2026.
- How has Bausch + Lomb's pharmaceuticals — operating income (loss) changed year-over-year?
- Bausch + Lomb's pharmaceuticals — operating income (loss) increased by 140.5% year-over-year, from $37M to $89M.
- What is the long-term trend for Bausch + Lomb's pharmaceuticals — operating income (loss)?
- Over 4 years (2021 to 2025), Bausch + Lomb's pharmaceuticals — operating income (loss) has grown at a -3.8% compound annual growth rate (CAGR), from $301M to $258M.
- What does pharmaceuticals — operating income (loss) mean?
- Measures the profitability of the pharmaceutical segment after deducting operating expenses from total revenues, excluding interest and taxes. It serves as the primary benchmark for evaluating the core operational performance and margin management of the pharmaceutical business unit.
Ask your AI about Bausch + Lomb's pharmaceuticals — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude